Certain embodiments are directed to methods for making programmable bioinspired nanoparticles (P-BiNP). Nanoparticles are coated with a cell membrane derived from a cell stimulated to express or overexpress a protein identified as being expressed in a target cell, forming a homotypic and organ targeted nanoparticle delivery vehicle.

Provided herein are nanoparticles including self-assembled cellular components derived from a homogenized plant tissue. Also provided are food powders and other related compositions. Methods for preparing such nanoparticles and food powders, as well as uses thereof in the treatment or prevention of diseases or disorders in a subject and/or as delivery vehicles are also described.

Disclosed herein are compositions and methods for cancer immunotherapy, and more particularly immune cells loaded with protein clusters and/or immunostimulatory fusion molecules (IFMs), in combination with an inhibitor of a checkpoint inhibitor.

Multi-layered particles and compositions comprising a compound are disclosed. Processes of preparing the particles and compositions and uses thereof are also disclosed.

A biomass-based encapsulating material for protection of probiotic activity and an encapsulating method are disclosed. The biomass-based encapsulating material includes a nano-film having two layers for encapsulating probiotics. A first layer is formed through natural biological macromolecules and metal ions on surfaces of the probiotics by covalent cross-linking or metal chelating action in situ, and a second layer is formed by interactions between a bio-enzyme and the natural biological macromolecules. The nano-film formed in situ on cell walls of probiotics is used for encapsulation and protection of probiotics. The nano-film is made of natural biomass, has low cost and has no toxic side effects. The relative activity of encapsulated probiotics is close to or higher than 90%, whether they are cultivated in environments under high concentration of antibiotics or active-free radicals. The relative activity of unprotected probiotics is below 30%, or even completely unable to survive.

Described herein are cell-free therapeutic compositions derived from blood or plasma and uses thereof for the treatment of selected diseases and disorders.

The Moringa oleifera nanoparticles may be synthesized by harvesting Moringa leaves, drying the Moringa leaves, powdering the dried Moringa leaves, suspending the powdered Moringa leaves in a solution, and spraying the solution into boiling water under ultrasonic conditions to obtain Moringa nanoparticles. The Moringa nanoparticles may be encapsulated by dissolving the Moringa nanoparticles and gum olibanum in ethanol to produce a mixture, injecting the inert organic phase of the mixture into an aqueous solution containing PVA, and homogenizing the aqueous solution. The Moringa nanoparticles may be useful in preventing the growth of cancer cells and in treating diabetes by inhibiting α-glucosidase and/or α-amylase activity.

Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived biomimetic nanovesicles (Hypo-BioNVs) or Hypo-exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers. A method of making Hypo-BioNVs. A method of treating an individual with cancer, by administering the Hypo-BioNVs to an individual, targeting cancer cells, and treating the cancer. Hypo-BioNVs including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus. A method of treating an individual with cancer, by administering Hypo-BioNVs including CAR receptors to an individual, targeting cancer cells, and treating the cancer. A method of targeting cells in an individual, by administering the Hypo-BioNVs to an individual, and targeting cells to be destroyed or treated for cancer tumors (both liquid and solid), infectious disease, hereditary conditions, autoimmune disease, or metabolic disorders.

A hydrophobic topical skin composition is disclosed. The composition includes greater than 50% w/w of the composition of a continuous hydrophobic carrier, 5-24% w/w of one or more volatile silicone fluids, and 0.1 to 5% w/w of the composition of a plurality of taxane nanoparticles, wherein the mean particle size (number) of the taxane nanoparticles is from 0.1 microns to 1.5 microns, and wherein the taxane nanoparticles are crystalline nanoparticles or a combination of amorphous and crystalline nanoparticles.

The disclosure features lipid nanoparticles (LNPs) comprising RNA interference agents, such as siRNAs, and methods of delivery thereof to immune cells. The compositions and methods can be used to modulate the activity of the immune cells to which the LNPs are delivered, such as to modulate regulatory or effector immune cell activity. Accordingly, the disclosure provides compositions and methods for modulating immune response, for example, to stimulate immune responses, such as in cancer and infectious diseases, or to inhibit immune responses, such as in autoimmune and inflammatory disorders.